CLEC2D and lung carcinoma: Indeed, CLEC2D and KLRB1 gene expressions (encoding for LLT1 and CD161, respectively) have been associated with better clinical outcomes for lung cancer patients, an observation that may be explained by the increased IFN-γ production of tumor-infiltrating CD161+ CD4+ T cells when compared to their CD161- counterparts [188].